30 Days Countdown: Record Global Participation Highlights CISCE's Commitment to Connectivity, Cooperation and Innovation
To date, 650+ companies and institutions from 75 countries and regions have confirmed their cooperation, with 35% of exhibitors coming from overseas—half of those from Europe and the U.S. Over 65% of participants are from Fortune 500 companies or industry leaders, while total exhibitor engagement—including supply chain affiliates—is projected to reach 1,200. The expo is expected to welcome 200,000+ professional and general visitors through both in-person and digital platforms.
Thailand has been named as this year's Guest Country of Honor, with China's Shandong and Guangdong provinces as Guest Provinces of Honor.
The landmark CISCE 2025 Beijing Initiative s will be unveiled during the event, while the third annual Global Supply Chain Promotion Report will also be released at the Expo, providing actionable insights for international cooperation.
Exhibitions will showcase breakthrough innovations and collaborative achievements across seven core sectors: Advanced Manufacturing, Smart Vehicle s, Green Agriculture, Clean Energy, Digital Technology, Healthy Living, and Supply Chain Services. A slate of forums and side events will bring together industry pioneers, thought leaders, and specialists to chart new frontiers for global industrial and supply chain cooperation.
Innovation will be front and center at CISCE 2025 with the debut of the Innovation Chain Zone, highlighting trailblazing work from 14 top-tier institutions, including WIPO and the China National Intellectual Property Administration, and demonstrating their end-to-end innovation ecosystems. The event will host 100+ global product launches and unveilings —a 10% increase from 2024—alongside the rollout of the CISCE New Product Hub, the Global Supply Chain Index Matrix, and a Visualized Industrial Map.
Upholding its commitment to eco-friendly, low-carbon, and sustainable operations, the Expo will offer exhibitors personalized concierge services, while providing visiting delegations with customized solutions. Registration is now open for trade visitors, buyers, media, and the general public, with free admission for all guests.
For more information, please visit https://en.cisce.org.cn/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
12 minutes ago
- Cision Canada
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
VANCOUVER, BC, July 10, 2025 /CNW/ -- USA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data, Maine currently has the highest rates among US states, while Utah has the lowest. However, another study found that survival rates for cancer patients on immunotherapy depend on their insurance coverage, whether it be through private, Medicaid, or those who are uninsured. With cases for several types of cancers, such as breast cancer, there is plenty of new tech innovation for diagnosis and treatments coming from the private sector. With public resources under pressure, and the cancer research budget for the National Cancer Institute set to be slashed by up to 40%, the oncology landscape is looking towards a new generation of biotechs to step up—including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Kazia Therapeutics Limited (NASDAQ: KZIA), Immuneering Corporation (NASDAQ: IMRX), Nuvation Bio Inc. (NYSE: NUVB), and Calidi Biotherapeutics Inc. (NYSE-American: CLDI). While U.S. cancer death rates continue to decline, global cancer cases are expected to rise sharply. As well, early-onset diagnoses in younger patients are climbing at a troubling pace. Now, industry analysts are estimating the global oncology drug market could surpass US$900 billion in revenue by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently highlighted survival data and an upcoming KOL webinar that together underscore growing expert and clinical support for its virus-based immunotherapy, pelareorep, in hard-to-treat cancers like metastatic pancreatic and breast cancer. In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), pelareorep-based treatment regimens have shown a two-year overall survival rate of 21.9% across pooled data from more than 100 patients—more than double the historical benchmark of 9.2%. In a separate single-arm study combining pelareorep with chemotherapy and a checkpoint inhibitor, the objective response rate reached 62% in evaluable patients. No immunotherapy is currently approved in this indication. "We are no longer in the business of funding proof-of-concept studies," said Jared Kelly, newly-appointed CEO of Oncolytics. "We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology." HR+/HER2- metastatic breast cancer (mBC) has also shown strong survival numbers. In HR+/HER2- mBC, pelareorep extended median overall survival by more than 10 months across two randomized trials. The BRACELET-1 trial also showed median progression-free survival of 12.1 months, nearly double the 6.4 months in the control arm. The company recently reinforced its leadership bench with two high-profile appointments—naming Jared Kelly as Chief Executive Officer and Andrew Aromando as Chief Business Officer —as it sharpens its focus on late-stage development and strategic transactions. Both Kelly and Aromando played instrumental roles in Ambrx Biopharma's $2 billion acquisition by Johnson & Johnson, and bring deep experience in value creation, partnerships, and registration pathways in oncology. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Oncolytics will host a KOL webinar on July 22 featuring leading GI and immuno-oncology experts to discuss pelareorep's data and positioning in pancreatic and gastrointestinal cancers. Participating physicians include the GOBLET trial's primary investigator as well as global leaders in immunotherapy and clinical trial design, underscoring the growing interest in pelareorep's mechanism and outcomes. Pelareorep currently holds FDA Fast Track designation in both mPDAC (pancreatic cancer) and HR+/HER2- mBC (breast cancer), with Orphan Drug status for pancreatic cancer in the U.S. and Europe. Across more than 1,100 patients treated to date, pelareorep has maintained a favorable safety profile, with most adverse events limited to flu-like symptoms. The drug has shown broad synergy with checkpoint inhibitors and chemotherapies and continues to generate immune responses in multiple solid tumor types. Oncolytics is advancing toward registration-enabling trials and partnership opportunities with a disciplined, investor-aligned approach to growth. In other recent industry developments and happenings in the market include: Kazia Therapeutics Limited (NASDAQ: KZIA) shared encouraging early data from its Phase 1b trial evaluating paxalisib alongside Keytruda and chemotherapy in triple-negative breast cancer. The first patient, a 61-year-old woman with lung metastases, experienced a greater than 50% reduction in circulating tumor cells (CTCs) after just one treatment cycle. "The degree of reduction in tumor cell dissemination markers in just 21 days gives us strong reason for optimism as we continue this clinical trial," said Dr. John Friend, MD, CEO of Kazia Therapeutics. "CTC clusters are emerging as key drivers of metastatic spread—they're 20–100X more efficient at seeding than single CTCs—and the sharp decline we're seeing is truly encouraging. We believe this combination may offer a meaningful early intervention against systemic disease progression." Notably, both single CTCs and clusters—key drivers of metastasis—were sharply reduced, along with the mesenchymal phenotype often linked to aggressive disease. These initial results echo Kazia's preclinical findings and hint at the potential for meaningful anti-metastatic activity early in treatment. Immuneering Corporation (NASDAQ: IMRX) has been granted a U.S. composition of matter patent for atebimetinib, a once-daily oral cancer drug designed to overcome resistance and deliver longer-lasting benefits. In an ongoing Phase 2a study, the drug showed a 94% six-month survival rate in first-line pancreatic cancer—compared to 67% with standard care—while maintaining a strong safety profile. "Our priorities are to make medicines that keep working, so cancer patients keep living, and to make medicines that have fewer side effects, so cancer patients can feel like themselves and live normal lives," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "We have already observed exceptional durability and a markedly favorable tolerability profile in first-line pancreatic cancer patients treated with atebimetinib+mGnP, and this is just the beginning of the important impact that we believe atebimetinib and our entire pipeline of deep cyclic inhibitors will have on the treatment of cancer." The patent provides exclusivity into 2042, with potential extension, supporting Immuneering's broader strategy to advance this "deep cyclic" MEK inhibitor across multiple tumor types. Nuvation Bio Inc. (NYSE: NUVB) has announced that IBTROZI (taletrectinib)—its newly FDA -approved targeted therapy for advanced ROS1+ non-small cell lung cancer (NSCLC)—has now been added as a Preferred Agent in the latest National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines. This designation applies to both first-line and follow-up treatment, and specifically highlights IBTROZI's benefit for patients with brain metastases and resistance mutations. "We are very pleased the NCCN acted with such urgency to review and update the NCCN Guidelines to include taletrectinib (IBTROZI) as a preferred option for advanced ROS1-positive NSCLC across treatment lines, with particular recognition of benefit for patients with brain metastases and those with acquired resistance after first-line therapy," said David Hung, M.D., Founder, President and CEO of Nuvation Bio. "These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights preferred utilization of ROS1-targeted agents instead of immunotherapy and chemotherapy for these patients." The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads to the brain. Calidi Biotherapeutics Inc. (NYSE-American: CLDI) is gaining traction as it advances CLD-401, a next-generation systemic virotherapy armed with CD55-enhanced shielding and an IL-15 superagonist payload to improve immune activation and tumor penetration. Preclinical data presented at ASCO 2025 showed the platform's potential to evade immune clearance, target metastatic tumors, and stimulate both NK and CD8+ T cell responses—supporting its promise as an off-the-shelf immunotherapy for difficult-to-treat cancers. The company recently secured $4.6 million in funding through warrant exercises and reaffirmed its IND submission timeline and partnering goals in a shareholder update. "Looking ahead, our roadmap for the next 18 months includes multiple critical milestones," said Eric Poma, PhD, CEO of Calidi in a shareholder letter. "We are working to complete IND-enabling studies ahead of an IND filing by the end of 2026 for our lead RedTail candidate that delivers IL15 superagonist to tumor sites, CLD-401. Our clinical strategy includes an aggressive dose-escalation study designed to swiftly demonstrate efficacy and validate the systemic administration of Redtail in patients with metastatic disease." With clinical readiness targeted for 2026, Calidi appears well-positioned at the intersection of innovation, execution, and immuno-oncology momentum. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
12 minutes ago
- Cision Canada
Micrologic recognized as a Representative Vendor on the 2025 Gartner® Market Guide for Digital Sovereignty Solutions Français
QUEBEC CITY, July 10, 2025 /CNW/ - Micrologic, a 100% Canadian-owned company who has built a sovereign cloud, is proud to announce that Gartner has recognized Micrologic as a Representative Vendor on the 2025 Gartner® Market Guide for Digital Sovereignty Solutions. We believe that this acknowledgment underscores Micrologic's commitment to providing secure, true sovereign cloud solutions that meet the highest standards of data sovereignty. As digital sovereignty becomes increasingly critical for organizations in the current geopolitical context, Micrologic continues to lead the way in delivering trusted and compliant cloud services tailored to the unique needs of large public and private organizations in the country. "As a leader in digital sovereignty solutions in Canada, we are excited to be acknowledged by Gartner. This recognition reflects our unwavering dedication to providing large public and private organizations with secure, sovereign cloud infrastructure that empowers them to innovate and grow with confidence. As the only Canadian provider in this category, we are proud to support the digital transformation of businesses across Canada while ensuring their data is subject exclusively to Canadian laws ‒ a major advantage in the face of growing threats of foreign interference", said Stephane Garneau, President & CEO of Micrologic. Gartner, Market Guide for Digital Sovereignty Solutions, By Dennis Smith, Rene Buest, Alessandro Galimberti, 5 May 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Micrologic Micrologic is a Canadian company that has been driving the digital transformation large private and public organizations for over 40 years. They have developed a Canadian sovereign cloud, which is powered by sustainable energy and is equipped with strict certifications. With a pan-Canadian expansion plan involving $150 million in investments, the company has increased its revenue tenfold over the past decade, generating over $1.5 billion in revenue. The company's president, Stéphane Garneau, has been recognized as CEO of the Year by Les Affaires and the Association québécoise des technologies, and was a finalist in the EY Entrepreneur of the Year Award.
Cision Canada
12 minutes ago
- Cision Canada
TP Receives Frost & Sullivan's 2025 North American Company of the Year Recognition for Excellence in Secure Innovation
Frost & Sullivan recognizes TP's AI-powered cybersecurity innovation, market leadership, and customer trust in safeguarding digital customer experiences across high-risk sectors. SAN ANTONIO, July 10, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that TP has been awarded the 2025 North American Company of the Year Recognition in the customer experience management industry for its outstanding achievements in advanced cybersecurity innovation, risk mitigation, and customer protection. This recognition highlights TP's consistent leadership in building a secure CX ecosystem that leverages proprietary AI technology to protect sensitive data, enhance digital trust, and deliver operational efficiency in a high-risk digital environment. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. TP excelled in both, demonstrating its ability to align AI-driven cybersecurity innovation with client needs while executing programs with precision, scalability, and resilience. "The company's cybersecurity strategy prioritizes real-time monitoring, rapid response, and automation. Its system detects unauthorized changes within an average of two minutes and mitigates them in less than 15 minutes. This level of responsiveness prevents service disruptions and ensures business continuity, a critical factor for clients relying on TP's secure environment," said Sebastian Menutti, Research Director at Frost & Sullivan. Guided by a long-term growth strategy centered on digital innovation and secure-by-design operations, TP has shown its ability to lead in an increasingly complex threat landscape. The company's commitment to proactive threat intelligence, compliance rigor, and real-time monitoring enables it to support mission-critical operations across regulated sectors, such as finance, healthcare, and retail. Innovation remains central to TP's approach. Its proprietary solution, TP Protect, is an advanced monitoring framework that leverages AI and machine learning to detect unauthorized keystrokes, data modification attempts, and fraudulent behavior in real time. This system is seamlessly integrated into the company's broader, AI-powered threat detection ecosystem. "At TP, we are proud to take a rigorous and holistic approach to security through our advanced frameworks, intelligent automation and by fostering a security-first culture," said Christian Muus, Global CISO at TP. "The Frost & Sullivan report recognizes TP as a trusted partner in security because of our proprietary solutions, proactive approach to cybersecurity, and ability to adapt quickly to evolving cyber threats." TP's unwavering commitment to customer protection reinforces its market position. By streamlining threat detection and response processes, enhancing fraud prevention across high-risk verticals, and fostering a culture of cybersecurity awareness, the company continuously delivers high-value outcomes. TP's collaborative approach—working alongside business process outsourcing (BPO) peers and regulatory bodies—has helped shape stronger cybersecurity practices across the entire CX management ecosystem. Frost & Sullivan commends TP for setting a new benchmark in secure CX leadership. The company's focus on AI innovation, strategic collaboration, and customer-centric protection continues to influence the best practices across the industry, ensuring that clients can operate securely at scale in a digital-first world. Each year, Frost & Sullivan presents the Cybersecurity Leadership Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in risk management, customer confidence, and competitive differentiation. The award recognizes forward-thinking organizations that are redefining cybersecurity practices through innovation and operational excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: E: [email protected] About Teleperformance Group Teleperformance (TEP – ISIN: FR0000051807 – Reuters: - Bloomberg: TEP FP), is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world's biggest brands and their customers. The Group's comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections, interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group's local presence allows it to be a force of good in supporting communities, clients, and the environment. In 2024, Teleperformance reported consolidated revenue of €10,280 million (US$11 billion) and net profit of €523 million. Teleperformance shares are traded on the Euronext Paris market, Compartment A, and are eligible for the deferred settlement service. They are included in the following indices: CAC 40, STOXX 600, S&P Europe 350, MSCI Global Standard and Euronext Tech Leaders. In the area of corporate social responsibility, Teleperformance shares are included in the CAC 40 ESG since September 2022, the Euronext Vigeo Euro 120 index since 2015, the MSCI Europe ESG Leaders index since 2019, the FTSE4Good index since 2018 and the S&P Global 1200 ESG index since 2017. For more information:
